Puma | pharmaphorum

Skip to main content

Friday 22 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Puma

News

Radiology technician examens mammography test on location

EU regulators reject Puma's Nerlynx breast cancer drug

European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.

News

Radiology technician examens mammography test on location

MacroGenics' HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g

News

trump_kentucky

Trump tax reform uncertainty puts biotech M&A on hold

Tesaro and Puma are potential takeover targets

News

Radiology technician examens mammography test on location

Victory for Puma as FDA approves breast cancer drug

Neratinib can be used to reduce risk of disease returning.

News

Roche Rituxan approval

Puma gains as Roche breast cancer combo disappoints

ASCO serves up shock as Roche's data disappoints

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA advisers back Puma breast cancer drug despite safety wor...

But biotech still has several hurdles to clear - including Roche's rival.

Load more results

Editor's Picks

Trump pick of RFK for top US health job astounds critics News

23andMe ends drug development and slashes staff

BioNTech buys Biotheus and its Keytruda rival for $950m

Chasing $80bn sales target, AZ unveils $3.5bn US investment News

London "is number one European city in life sciences"

News

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys

Sales & Marketing

Happy lady reading from tablet

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company